FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2766048691> ?p ?o ?g. }

• W2766048691 endingPage "e0186587" @default.
• W2766048691 startingPage "e0186587" @default.
• W2766048691 abstract "Scleroderma has clinical characteristics including skin and other tissue fibrosis, but there is an unmet need for anti-fibrotic therapy. Halofuginone (HF) is a well-known anti-fibrosis agent in preclinical and clinical studies which exerts its effect via inhibition of TGF-β/Smad3 signaling pathway. Recently, prolyl-tRNA synthetase (PRS) was elucidated as a target protein for HF that binds to the proline binding site of the catalytic domain of PRS. Here, we characterized a new class of PRS inhibitor (T-3833261) that is carefully designed in a way that binds to the ATP site of the catalytic domain and does not disrupt binding of proline. The anti-fibrotic activity and the mechanism of action for T-3833261 on TGF-β-induced fibrotic assay were compared with those of HF in primary human skin fibroblast. We evaluated in vivo effect of topical application of T-3833261 and HF on TGF-β-induced fibrotic genes expression in mice. We found that T-3833261 suppressed TGF-β-induced α-smooth muscle actin (α-SMA) and type I collagen α1 (COL1A1) expression through the Smad3 axis in a similar fashion to HF. In vivo topical application of T-3833261 reduced the increase of fibrotic genes expression such as α-Sma, Col1a1 and Col1a2 by TGF-β intradermal injection to the ear of a mouse. We revealed that T-3833261 is more effective than HF under the conditions of high proline concentration, as reported in fibrotic tissues. These results suggest the potential of ATP competitive PRS inhibitors for the treatment of fibrotic diseases such as scleroderma." @default.
• W2766048691 created "2017-11-10" @default.
• W2766048691 creator A5005015007 @default.
• W2766048691 creator A5010506067 @default.
• W2766048691 creator A5033261098 @default.
• W2766048691 creator A5037632984 @default.
• W2766048691 creator A5044969186 @default.
• W2766048691 creator A5047300316 @default.
• W2766048691 creator A5051071453 @default.
• W2766048691 creator A5051819621 @default.
• W2766048691 creator A5063539466 @default.
• W2766048691 creator A5063705591 @default.
• W2766048691 creator A5077898527 @default.
• W2766048691 creator A5085869635 @default.
• W2766048691 date "2017-10-24" @default.
• W2766048691 modified "2023-10-05" @default.
• W2766048691 title "Discovery and pharmacological characterization of a new class of prolyl-tRNA synthetase inhibitor for anti-fibrosis therapy" @default.
• W2766048691 cites W1888470382 @default.
• W2766048691 cites W1916800927 @default.
• W2766048691 cites W1970719879 @default.
• W2766048691 cites W1975318062 @default.
• W2766048691 cites W1985980869 @default.
• W2766048691 cites W1992963028 @default.
• W2766048691 cites W1997219424 @default.
• W2766048691 cites W2003569218 @default.
• W2766048691 cites W2005008773 @default.
• W2766048691 cites W2008253803 @default.
• W2766048691 cites W2020010164 @default.
• W2766048691 cites W2023752082 @default.
• W2766048691 cites W2026626409 @default.
• W2766048691 cites W2029907535 @default.
• W2766048691 cites W2041286014 @default.
• W2766048691 cites W2049659786 @default.
• W2766048691 cites W2050906087 @default.
• W2766048691 cites W2073653948 @default.
• W2766048691 cites W2083620310 @default.
• W2766048691 cites W2096522371 @default.
• W2766048691 cites W2103133688 @default.
• W2766048691 cites W2125105859 @default.
• W2766048691 cites W2133485412 @default.
• W2766048691 cites W2138705006 @default.
• W2766048691 cites W2147084913 @default.
• W2766048691 cites W2152739288 @default.
• W2766048691 cites W2155049325 @default.
• W2766048691 cites W2164397421 @default.
• W2766048691 cites W2177104438 @default.
• W2766048691 cites W2565662091 @default.
• W2766048691 cites W2578571452 @default.
• W2766048691 cites W2612257830 @default.
• W2766048691 cites W4254553512 @default.
• W2766048691 doi "https://doi.org/10.1371/journal.pone.0186587" @default.
• W2766048691 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5655428" @default.
• W2766048691 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29065190" @default.
• W2766048691 hasPublicationYear "2017" @default.
• W2766048691 type Work @default.
• W2766048691 sameAs 2766048691 @default.
• W2766048691 citedByCount "19" @default.
• W2766048691 countsByYear W27660486912018 @default.
• W2766048691 countsByYear W27660486912019 @default.
• W2766048691 countsByYear W27660486912020 @default.
• W2766048691 countsByYear W27660486912021 @default.
• W2766048691 countsByYear W27660486912022 @default.
• W2766048691 countsByYear W27660486912023 @default.
• W2766048691 crossrefType "journal-article" @default.
• W2766048691 hasAuthorship W2766048691A5005015007 @default.
• W2766048691 hasAuthorship W2766048691A5010506067 @default.
• W2766048691 hasAuthorship W2766048691A5033261098 @default.
• W2766048691 hasAuthorship W2766048691A5037632984 @default.
• W2766048691 hasAuthorship W2766048691A5044969186 @default.
• W2766048691 hasAuthorship W2766048691A5047300316 @default.
• W2766048691 hasAuthorship W2766048691A5051071453 @default.
• W2766048691 hasAuthorship W2766048691A5051819621 @default.
• W2766048691 hasAuthorship W2766048691A5063539466 @default.
• W2766048691 hasAuthorship W2766048691A5063705591 @default.
• W2766048691 hasAuthorship W2766048691A5077898527 @default.
• W2766048691 hasAuthorship W2766048691A5085869635 @default.
• W2766048691 hasBestOaLocation W27660486911 @default.
• W2766048691 hasConcept C142724271 @default.
• W2766048691 hasConcept C153911025 @default.
• W2766048691 hasConcept C185592680 @default.
• W2766048691 hasConcept C207001950 @default.
• W2766048691 hasConcept C2779815552 @default.
• W2766048691 hasConcept C2780559512 @default.
• W2766048691 hasConcept C502942594 @default.
• W2766048691 hasConcept C515207424 @default.
• W2766048691 hasConcept C54355233 @default.
• W2766048691 hasConcept C55493867 @default.
• W2766048691 hasConcept C71924100 @default.
• W2766048691 hasConcept C86803240 @default.
• W2766048691 hasConcept C98274493 @default.
• W2766048691 hasConceptScore W2766048691C142724271 @default.
• W2766048691 hasConceptScore W2766048691C153911025 @default.
• W2766048691 hasConceptScore W2766048691C185592680 @default.
• W2766048691 hasConceptScore W2766048691C207001950 @default.
• W2766048691 hasConceptScore W2766048691C2779815552 @default.
• W2766048691 hasConceptScore W2766048691C2780559512 @default.
• W2766048691 hasConceptScore W2766048691C502942594 @default.
• W2766048691 hasConceptScore W2766048691C515207424 @default.

• next